Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsJonathan Emberson, Werner Hacke, Erich Bluhmki et al.|The Lancet|2014Cited by 2.7k
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialStephen Phillips, Peter Sandercock, Joanna M. Wardlaw et al.|The Lancet|2012Cited by 1.2k
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisJoanna M. Wardlaw, Geoff Cohen, Veronica Murray et al.|The Lancet|2012Cited by 1k